InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

Current share price for OSL : $1.015 0.045 (4.64%)+

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 Notice under ASX Listing Rule 3.10A 15 Sep 2026 9:04AM $0.980 $1.015 risen by 3.57%
$37 Change in substantial holding 14 Sep 2026 4:52PM $0.980 $1.015 risen by 3.57%
$37 Change in substantial shareholding from AEF 14 Sep 2026 8:39AM $0.975 $1.015 risen by 4.10%
$37 Notice Under Section 708A 10 Sep 2026 11:21AM $1.040 $1.015 fallen by 2.40%
$37 Application for quotation of securities - OSL 10 Sep 2026 11:20AM $1.040 $1.015 fallen by 2.40%
$37 Application for quotation of securities - OSL 10 Sep 2026 11:16AM $1.040 $1.015 fallen by 2.40%
$37 Australian Manufacturing Facility Achieves ISO 13485 9 Sep 2026 8:43AM $1.065 $1.015 fallen by 4.69%
$37 100th Patient Treated with OncoSil device in Spain 8 Sep 2026 9:40AM $0.910 $1.015 risen by 11.54%
$37 Proposed issue of securities - OSL 7 Sep 2026 5:12PM $0.910 $1.015 risen by 11.54%
$37 OSL Secures $5.6 million from Major Institutional Investors 7 Sep 2026 5:11PM $0.910 $1.015 risen by 11.54%
$37 OncoSil submits US Reimbursement Application (Updated) 2 Sep 2026 11:33AM $1.065 $1.015 fallen by 4.69%
$37 OncoSil submits US Reimbursement Application 2 Sep 2026 10:27AM $1.070 $1.015 fallen by 5.14%
$37 Appendix 4G and Corporate Governance Statement 28 Aug 2026 4:03PM $1.175 $1.015 fallen by 13.62%
$37 Appendix 4E and Annual Report 28 Aug 2026 3:58PM $1.175 $1.015 fallen by 13.62%
$37 Change in substantial holding 21 Aug 2026 4:52PM $1.150 $1.015 fallen by 11.74%
$37 Change in substantial shareholding from AEF 20 Aug 2026 9:22AM $1.150 $1.015 fallen by 11.74%
$37 Application for quotation of securities - OSL 17 Aug 2026 4:46PM $1.200 $1.015 fallen by 15.42%
$37 Investor Webinar Presentation 17 Aug 2026 3:09PM $1.200 $1.015 fallen by 15.42%
$37 OncoSil Receives FDA Approval for Distal Cholangiocarcinoma 17 Aug 2026 8:35AM $1.270 $1.015 fallen by 20.08%
$37 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2026 8:42AM $1.110 $1.015 fallen by 8.56%
$37 New Independent Study Confirms OncoSil Dose Flexibility 24 Jul 2026 8:40AM $1.300 $1.015 fallen by 21.92%
$37 Application for quotation of securities - OSL 23 Jul 2026 3:25PM $1.305 $1.015 fallen by 22.22%
$37 OncoSil Medical Receives Saudi Arabia FDA Approval 20 Jul 2026 8:31AM $1.450 $1.015 fallen by 30%
$37 Application for quotation of securities - OSL 17 Jul 2026 3:31PM $1.460 $1.015 fallen by 30.48%
$37 Investor Presentation 15 Jul 2026 8:57AM $1.375 $1.015 fallen by 26.18%

1 - 25 of 810 results

Page 1 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.